Goodwill - First Wave BioPharma Inc (NASDAQ:ENTO)

Watchlist Manager

Watchlist

Price: 2.85 USD -5.32%

Market Cap: $9.6m

First Wave BioPharma Inc
Goodwill

Quarterly

Annual

Adjust for Inflation

Balance Sheet

First Wave BioPharma Inc
Goodwill Peer Comparison

	Goodwill	CAGR 3Y	CAGR 5Y	CAGR 10Y
First Wave BioPharma Inc NASDAQ:ENTO	Goodwill $1.7m	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
Abbvie Inc NYSE:ABBV	Goodwill $35.6B	CAGR 3-Years 4%	CAGR 5-Years -4%	CAGR 10-Years 10%
Gilead Sciences Inc NASDAQ:GILD	Goodwill $8.3B	CAGR 3-Years 0%	CAGR 5-Years 15%	CAGR 10-Years 22%
Amgen Inc NASDAQ:AMGN	Goodwill $18.7B	CAGR 3-Years 8%	CAGR 5-Years 5%	CAGR 10-Years 2%
Vertex Pharmaceuticals Inc NASDAQ:VRTX	Goodwill $1.5B	CAGR 3-Years 12%	CAGR 5-Years 9%	CAGR 10-Years 41%
Regeneron Pharmaceuticals Inc NASDAQ:REGN	Goodwill N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A

First Wave BioPharma Inc
Glance View

Market Cap

9.6m USD

Industry

Biotechnology

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 17 full-time employees. The company went IPO on 2016-10-11. The firm is focused on developing its pipeline of gut-restricted GI clinical product candidates, including niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, which is a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The firm is advancing two separate clinical programs of niclosamide formulations, both of which are in Phase II clinical trials, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis. The adrulipase programs is focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

View ENTO Analysis

ENTO Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

The AI Assistant may sometimes provide inaccurate information.

Make your own investment decisions or consult a licensed financial advisor.

First Wave BioPharma Inc
NASDAQ:ENTO

First Wave BioPharma Inc
Goodwill

First Wave BioPharma Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

First Wave BioPharma Inc
Glance View

See Also

Company

Help

Tools

Stocks

52 Week Range	1.0221 5.63
Price Target

First Wave BioPharma Inc NASDAQ:ENTO

First Wave BioPharma Inc Goodwill

First Wave BioPharma Inc Goodwill Peer Comparison

Competitors Analysis Latest Figures & CAGR of Competitors

First Wave BioPharma Inc Glance View

See Also

Company

Help

Tools

Stocks

First Wave BioPharma Inc
NASDAQ:ENTO

First Wave BioPharma Inc
Goodwill

First Wave BioPharma Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

First Wave BioPharma Inc
Glance View